Phase I/II open-label trial to evaluate the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)